


## Retapamulin

Cat. No.:	HY-17010
CAS No.:	224452-66-8
Molecular Formula:	C <sub>30</sub> H <sub>47</sub> NO <sub>4</sub> S
Molecular Weight:	517.76
Target:	Bacterial; Antibiotic
Pathway:	Anti-infection
Storage:	4°C, protect from light * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)



### SOLVENT & SOLUBILITY

In Vitro	DMSO : 110 mg/mL (212.45 mM; Need ultrasonic)						
	Preparing Stock Solutions	Solvent Concentration	Mass	1 mg	5 mg	10 mg	
				1 mM	1.9314 mL	9.6570 mL	19.3140 mL
				5 mM	0.3863 mL	1.9314 mL	3.8628 mL
				10 mM	0.1931 mL	0.9657 mL	1.9314 mL
Please refer to the solubility information to select the appropriate solvent.							
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.75 mg/mL (5.31 mM); Clear solution						
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.75 mg/mL (5.31 mM); Clear solution						
	3. Add each solvent one by one: 10% DMSO >> 90% corn oil Solubility: ≥ 2.75 mg/mL (5.31 mM); Clear solution						

### BIOLOGICAL ACTIVITY

Description	Retapamulin(SB-275833) is a topical antibiotic, which binds to both E. coli and S. aureus ribosomes with similar potencies with Kd of 3 nM. IC50 Value: 3 nM(Kd, E.coli)Target: Antibacterial Retapamulin is a topical antibiotic developed by GlaxoSmithKline. Retapamulin(SB-275833) is the first drug in the new class of pleuromutilin antibiotics to be approved for human use. Retapamulin(SB-275833) is marketed as an ointment under the brand names Altanax and Altargo. Retapamulin(SB-275833) is useful for Antibiotics.
-------------	---

### CUSTOMER VALIDATION

- Microb Biotechnol. 2021 Mar 15.
- J Antibiot. 2020 Sep;73(9):630-635.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

## REFERENCES

---

- [1]. Kircik LH. Efficacy and tolerability of retapamulin 1% ointment for the treatment of infected atopic dermatitis: a pilot study. *J Drugs Dermatol*. 2012 Jul 1;11(7):858-60.
- [2]. Candel FJ, Morales G, Picazo JJ. In vitro activity of retapamulin against linezolid and methicillin-resistant *Staphylococcus aureus* isolates. *Rev Esp Quimioter*. 2011 Sep;24(3):127-30.
- [3]. Pérez-Trallero E, Tamayo E, Montes M, García-Arenzana JM, Iriarte V. In vitro activities of retapamulin and 16 other antimicrobial agents against recently obtained *Streptococcus pyogenes* isolates. *Antimicrob Agents Chemother*. 2011 May;55(5):2406-8.
- [4]. Weinberg JM, Tyring SK. Retapamulin: an antibacterial with a novel mode of action in an age of emerging resistance to *Staphylococcus aureus*. *J Drugs Dermatol*. 2010 Oct;9(10):1198-204.
- [5]. Retapamulin: focus on its use in the treatment of uncomplicated superficial skin infections and impetigo By Jacobs, Michael R. From *Expert Review of Dermatology* (2010), 5(5), 505-517.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA